Carbohydrate-based particles reduce allergic inflammation in a mouse model for cat allergy

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 63, Issue 5, 2008, Pages 518-526

  Neimert Andersson, T ^a   Thunberg, S ^a   Swedin, L ^a   Wiedermann, U ^b   Jacobsson Ekman, G ^a   Dahlen S E ^a   Scheynius, A ^a   Gronlund H ^a   Hage, M Van ^a   Gafvelin, G ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Allergen specific immunotherapy; Allergy model; Fel d 1; Particulate adjuvans

Indexed keywords

CARBOHYDRATE; CARBOHYDRATE BASED PARTICLE; IMMUNOGLOBULIN G2; RECOMBINANT ALLERGEN; RECOMBINANT ALLERGEN FEL D 1; UNCLASSIFIED DRUG;

AIRWAY CONDUCTANCE; ALLERGY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; CAT; FEMALE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; INFLAMMATION; LUNG LAVAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BRONCHIAL HYPERREACTIVITY; CARBOHYDRATES; CATS; DESENSITIZATION, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; FEMALE; GLYCOPROTEINS; HUMANS; HYPERSENSITIVITY, IMMEDIATE; INFLAMMATION; MICE; MICE, INBRED BALB C; PARTICLE SIZE; RATS; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 41749086951     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2008.01644.x     Document Type: Article

References (31)

1. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2007 119 : 780 791.
2. Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006 6 : 761 771.
3. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol 2004 113 : 1025 1034.
4. Winther L, Arnved J, Malling HJ, Nolte H, Mosbech H. Side-effects of allergen-specific immunotherapy. A prospective multi-centre study. Clin Exp Allergy 2006 36 : 254 260.
5. Brewer JM. (How) do aluminium adjuvants work? Immunol Lett 2006 102 : 10 15.
6. Exley C. Aluminium-adsorbed vaccines. Lancet Infect Dis 2006 6 : 189.
7. Vrtala S, Akdis CA, Budak F, Akdis M, Blaser K, Kraft D et al. T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies. J Immunol 2000 165 : 6653 6659.
8. Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, Valent P et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A 2004 101 (Suppl 2 14677 14682.
9. Saarne T, Kaiser L, Gronlund H, Rasool O, Gafvelin G, van Hage-Hamsten M. Rational design of hypoallergens applied to the major cat allergen Fel d 1. Clin Exp Allergy 2005 35 : 657 663.
10. Tarzi M, Klunker S, Texier C, Verhoef A, Stapel SO, Akdis CA et al. Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin Exp Allergy 2006 36 : 465 474.
11. Francis JN, Larche M. Peptide-based vaccination: where do we stand? Curr Opin Allergy Clin Immunol 2005 5 : 537 543.
12. Terada T, Zhang K, Belperio J, Londhe V, Saxon A. A chimeric human-cat Fcgamma-Fel d1 fusion protein inhibits systemic, pulmonary, and cutaneous allergic reactivity to intratracheal challenge in mice sensitized to Fel d1, the major cat allergen. Clin Immunol 2006 120 : 45 56.
13. Zhu D, Kepley CL, Zhang K, Terada T, Yamada T, Saxon A. A chimeric human-cat fusion protein blocks cat-induced allergy. Nat Med 2005 11 : 446 449.
14. Santeliz JV, Van Nest G, Traquina P, Larsen E, Wills-Karp M. Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J Allergy Clin Immunol 2002 109 : 455 462.
15. Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006 355 : 1445 1455.
16. Mothes N, Heinzkill M, Drachenberg KJ, Sperr WR, Krauth MT, Majlesi Y et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003 33 : 1198 1208.
17. Gronlund H, Vrtala S, Wiedermann U, Dekan G, Kraft D, Valenta R et al. Carbohydrate-based particles: a new adjuvant for allergen-specific immunotherapy. Immunology 2002 107 : 523 529.
18. Andersson TN, Ekman GJ, Gronlund H, Buentke E, Eriksson TL, Scheynius A et al. A novel adjuvant-allergen complex, CBP-rFel d 1, induces up-regulation of CD86 expression and enhances cytokine release by human dendritic cells in vitro. Immunology 2004 113 : 253 259.
19. Gronlund H, Bergman T, Sandstrom K, Alvelius G, Reininger R, Verdino P et al. Formation of disulfide bonds and homodimers of the major cat allergen Fel d 1 equivalent to the natural allergen by expression in Escherichia coli. J Biol Chem 2003 278 : 40144 40151.
20. Johansson E, Johansson SG, Van Hage-Hamsten M. Allergenic characterization of Acarus siro and Tyrophagus putrescentiae and their crossreactivity with Lepidoglyphus destructor and Dermatophagoides pteronyssinus. Clin Exp Allergy 1994 24 : 743 751.
21. Hjoberg J, Shore S, Kobzik L, Okinaga S, Hallock A, Vallone J et al. Expression of nitric oxide synthase-2 in the lungs decreases airway resistance and responsiveness. J Appl Physiol 2004 97 : 249 259.
22. Parvaneh S, Johansson E, Elfman LH, van Hage-Hamsten M. An ELISA for recombinant Lepidoglyphus destructor, Lep d 2, and the monitoring of exposure to dust mite allergens in farming households. Clin Exp Allergy 2002 32 : 80 86.
23. Repa A, Wild C, Hufnagl K, Winkler B, Bohle B, Pollak A et al. Influence of the route of sensitization on local and systemic immune responses in a murine model of type I allergy. Clin Exp Immunol 2004 137 : 12 18.
24. Trollfors B, Bergfors E, Inerot A. Vaccine related itching nodules and hypersensitivity to aluminium. Vaccine 2005 23 : 975 976.
25. Bergfors E, Bjorkelund C, Trollfors B. Nineteen cases of persistent pruritic nodules and contact allergy to aluminium after injection of commonly used aluminium-adsorbed vaccines. Eur J Pediatr 2005 164 : 691 697.
26. Treter S, Luqman M. Antigen-specific T cell tolerance down-regulates mast cell responses in vivo. Cell Immunol 2000 206 : 116 124.
27. Kovacsovics-Bankowski M, Clark K, Benacerraf B, Rock KL. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci USA 1993 90 : 4942 4946.
28. Xiang SD, Scholzen A, Minigo G, David C, Apostolopoulos V, Mottram PL et al. Pathogen recognition and development of particulate vaccines: does size matter? Methods 2006 40 : 1 9.
29. Akdis M. Healthy immune response to allergens: T-regulatory cells and more. Curr Opin Immunol 2006 18 : 738 744.
30. Jutel M, Akdis M, Blaser K, Akdis CA. Mechanisms of allergen specific immunotherapy - T-cell tolerance and more. Allergy 2006 61 : 796 807.
31. Kundig TM, Senti G, Schnetzler G, Wolf C, Prinz Vavricka BM, Fulurija A et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 2006 117 : 1470 1476.